ERBB2 and neoplasm: One component of this dual system (VSVΔ51) delivers a synthetic HER2 target to tumors, making them susceptible to an ADC called T-DM1, while the other virus (VV) expresses a HER2-targeted TCE to redirect T cells to attack the tumor.